B. Braun announced that it is closing down a specialized medical device subsidiary and division.
B. Braun Interventional Systems, which is based at the company’s Bethlehem headquarters, will continue deliveries through March. The closure will affect 40 employees nationwide, though the exact number in the Lehigh Valley was not revealed.
BIS develops and manufactures specialized medical devices used in clinical fields such as interventional radiology, pediatric and congenital interventional cardiology, vascular surgery and pulmonology.
“B. Braun recently announced the decision to wind down and close B. Braun Interventional Systems as part of its ongoing efforts to focus resources on strategic priorities and core businesses,” B. Braun spokesperson Alli Longenhagen told The Morning Call. “The closure will occur through a phased transition, with commercial sales expected to continue into early 2027. Transition support services will be provided to the approximately 40 employees across the U.S. who will be impacted.”
The company said there is no immediate disruption to product supply. During the transition, BIS will continue supporting its customers and will work with suppliers to develop an orderly transition to new distributors where appropriate.
In June, B. Braun announced that it is closing two sites in Upper Macungie Township, affecting 173 jobs. Central Admixture Pharmacy Services Inc. at 6580 and 6845 Snowdrift Road just off Tilghman Street.
Texas-based QuVa Pharma Inc., which has a manufacturing facility in Bloomsbury, New Jersey acquired a range of essential medications from CAPS in September.
“Earlier this year, CAPS announced its decision to exit the 503B sterile compounding business, affecting its 503B operations in the Lehigh Valley and Phoenix,” Longenhagen said. “CAPS continues to invest in and operate its nationwide 503A pharmacy network.”